Enzymatica AB: ColdZyme® sales continue to perform well
Interim report forEnzymatica AB (publ)January-September 2016 ColdZyme[®] sales continue to perform well Q3 · Net sales reached SEK 12.3 (6.8) million. · Loss after tax came in at SEK -6.5 (-10.1) million. · Earnings per share were SEK -0.08 (-0.41). · Cash and cash equivalents were SEK 49.9 (9.7) million. Significant events in Q3 · Enzymatica completed a directed share issue, raising SEK 40 million before issue expenses. Significant events after Q3 · Enzymatica signed exclusive agreements for Australia, New Zeeland, Greece and Cyprus. First nine